External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology Hawaiian Eye 2024
Roche and Genentech at

Hawaiian Eye 2024

January 13 - January 19
Hawaii, USA
healio.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Jan 20 / Roche and Genentech
Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab▼: The FARETINA-AMD Study
This presentation describes results from the FARETINA-AMD study which is a retrospective real world study using data from the IRIS registry. Data were analyzed February 2022 - June 2023 to identify faricimab▼ starts among patients diagnosed with nAMD from the US. Results show that disease control was observed after 2 injections, and with each successive injection, with stable vision in previously treated eyes and vision improvement in treatment-naïve eyes. Early treatment extensions may indicate positive anatomical responses to faricimab▼ in patients with nAMD.
Ophthalmology Age Related Macular Degeneration Hawaiian-Eye-2024

Sign up or login to unlock the full suite of MEDICALLY features
Jan 20 / Roche and Genentech
Real-World Clinical and Anatomical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab▼: The FARETINA-DME Study
This presentation describes results from the FARETINA-DME study which is a retrospective real world study using data from the IRIS registry. Data were analyzed February 2022 - June 2023 to identify faricimab▼ starts among patients diagnosed with DME from the US. Results show that disease control was observed after 2 injections, and with each successive injection, with stable vision in previously treated eyes and vision improvement in treatment-naïve eyes. Early treatment extensions may indicate positive anatomical responses to faricimab▼ in patients with DME.
Ophthalmology Diabetic Macular Edema Hawaiian-Eye-2024

Sign up or login to unlock the full suite of MEDICALLY features
Jan 20 / Roche and Genentech
Impact of Faricimab▼ vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials
This presentation assesses the impact of extended faricimab▼ treatment intervals (≥ Q12W) on visual and anatomical outcomes in the phase 3 YOSEMITE/RHINE and TENAYA/LUCERNE trials, and evaluates how many patients could have been extended to Q20W dosing had the trials allowed. It also explores baseline characteristics that may predict whether patients could meet potential Q20W dosing criteria.
Ophthalmology Diabetic Macular Edema Hawaiian-Eye-2024
08:16 PM
Duration 6mins Session: Abstract Presentations
Faster Time to Retinal Fluid Control With Faricimab▼ vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Talcott K*, Finn A, Walter S, Lanzetta P, Rachitskaya A, Amador M, Camino A, Gibson K, Idowu O, Mar F, Tang Y
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:03 PM
Duration 6mins Session: Abstract Presentations
Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab▼: The FARETINA-AMD Study
Ali F*, Tabano D, Garmo V, Borkar D, Leng T, Shaia J, Kuo B, Myers R, LaPrise A, Ali F, Singh R
Ophthalmology | Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:11 PM
Duration 6mins Session: Abstract Presentations
Faricimab▼ Extended Dosing in the Phase 3 YOSEMITE/RHINE and TENAYA/LUCERNE Trials
Singer M*, Amador M, Hill L, Patel S, Sim D, Gibson K, Margaron P
Ophthalmology | Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:19 PM
Duration 6mins Session: Abstract Presentations
Real-World Clinical and Anatomical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab▼: The FARETINA-DME Study
Borkar D*, Tabano D, Garmo V, Leng T, Shaia J, Kuo B, Myers R, LaPrise A, Ali F, Singh R
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:03 PM
Duration 6mins Session: Abstract Presentations
Impact of Faricimab▼ vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials
Nudleman E*, Jaffe G, Ogura Y, Deak G, Gibson K, Schmidt-Erfurth U, Wang T, Westenskow P, Willis J
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:19 PM
Duration 6mins Session: Abstract Presentations
Biomarkers for vascular stability and inflammation demonstrate the benefit of dual Ang-2/VEGF-A inhibition with faricimab▼ Phase 3 trials in DME
Graff J*, Patel K, Wang T, Willis J, Gibson K, Mar F, Amador M, von Schulthess E, Maunz A, Glittenberg C
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:27 PM
Duration 6mins Session: Abstract Presentations
Changes in Intraocular Angiopoietin-2 and VEGF-A Following Faricimab▼ Treatment in nAMD and DME
Rahimy E*, Avery R; Cheung G, Bogman K, Stoilov I, Diack C
Ophthalmology | Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.